CRB-913 - (CANYON-1)

May 12, 2026: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) provided a corporate update and Q1 2026 financial results, highlighting upcoming catalysts for oncology program CRB-701 and obesity program CRB-913.

CRB-701 (Nectin-4–targeting ADC; HNSCC and cervical cancer): Corbus said it has reached broad alignment with the FDA on the registration path for CRB-701 in second-line head and neck squamous cell carcinoma (HNSCC) and cervical cancer, and is continuing FDA interactions to finalize registrational-study protocols and statistical analysis plans. Catalysts in 2026 include presentation of updated monotherapy Phase 1/2 data in HNSCC and cervical cancer at the 2026 ASCO annual meeting, and initiation of a registrational study in second-line HNSCC in summer 2026. The company also expects to report CRB-701 + Keytruda combination data in first-line HNSCC in early Q1 2027 to support potential further registration-enabling trials. FDA Fast Track designations were noted for both cancer types.

CRB-913 (oral, peripherally restricted CB1 inverse agonist; obesity): Corbus completed last-patient enrollment/first visit in the CANYON-1 Phase 1b trial; topline results from the 16-week dose-ranging study (n=240) are expected in summer 2026.

Financials: Q1 2026 net loss was ~$23.0M; cash/cash equivalents/investments were $138.2M as of March 31, 2026, expected to fund operations into 2028.